The burden of obesity in type 1 diabetic subjects: a sex-specific analysis from the AMD Annals Initiative
Giandalia A, Russo GT, Ruggeri P, et al.
J Clin Endocrinol Metab. 2023;dgad302.
Leggi
Breaking news
Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial
Hundertmark MJ, Adler A, Antoniades C, et al.
Circulation. 2023;147(22):1654-1669.
Leggi
Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
Stougaard EB, Rossing P, Vistisen D, et al.
Diabetes Obes Metab. 2023;25(7):1874-1882.
Leggi
Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis
Keidai Y, Yoshiji S, Hasebe M, et al.
Diabetes Obes Metab. Pub. online 22 May 2023.
Leggi
Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial
Saxena AR, Frias JP, Brown LS, et al.
JAMA Netw Open. 2023;6(5):e2314493.
Leggi
Risk prediction of gestational diabetes mellitus in women with polycystic ovary syndrome based on a nomogram model
Ouyang P, Duan S, You Y, et al.
BMC Pregnancy Childbirth. 2023;23(1):408
Leggi
Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes
Essien UR, Singh B, Swabe G, et al.
JAMA Netw Open. 2023;6(6):e2316290.
Leggi
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe
Pennells L, Kaptoge S, Bleken H, et al.
Eur Heart J. Pub. online 29 May 2023.
Leggi
Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets
Benhalima K, Beunen K, Siegelaar SE, et al.
The Lancet Diabetes & Endocrinology. Pub. online 5 Jun 2023.
Leggi
Dapagliflozin and diuretic utilization in heartfailure with mildly reduced or preserved ejection fraction: the DELIVER trial
Chatur S, Vaduganathan M, Claggett B, et al.
Eur Heart J. Pub. online 23 May 2023.
Leggi